山东新华制药股份2024年年报

目錄CONTENTS 2Company Information5Summary of Financial and Operating Results9Changes in Share Capital Structure and Information onShareholders17Directors, Supervisors, Senior Officers and Staff30Corporate Governance and Internal Control Report60Summarised Report of the General Meetings63Chairman’s Statement68Management Discussion and Analysis90Report of the Board of Directors129Environmental and Social Responsibility142Report of the Supervisory Committee146Important Issues157Financial Report416Documents Available for Inspection 202412 31 Important: The board of directors (“Board ofD i r e c t o r s ” )a n d t h e s u p e r v i s o r ycommittee (“Supervisory Committee”)and each of the directors (“Directors”),the supervisors (“Supervisors”) and thesenior management (collectively, the“Senior Officers”) of Shandong XinhuaPharmaceutical Company Limited(the “Company”) hereby confirm thatthere are no false representations,material omissions or misleadingstatements contained in this report,and they, severally and jointly, acceptfull responsibility for the truthfulness,accuracy and completeness of thecontents of this report. The chairman (Mr. He Tongqing),financial controller (Mr. Hou Ning) andthe chief of the finance department (Mr.He Xiaohong) of the Company herebydeclare that the financial report of theCompany for the financial year ended 31December 2024 (the “Reporting Period”)is true and complete. This report has been prepared in bothChinese and English. In the event of anydiscrepancy between the two versions,the Chinese version shall prevail. COMPANY INFORMATION SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITEDMr. He TongqingMr. Cao Changqiu86-533-216666686-533-2287508CQCAO@XHZY. COM(“”)Chemical Industry Area of Zibo Hi-tech Industry Development Zone,Zibo City, Shandong Province, The People’s Republic of China (the“PRC”)1No. 1 Lutai Ave., Hi-tech Industry Development Zone, Zibo City,Shandong Province, PRC255086http://www.xhzy.comxhzy@xhzy.comSecurities Times:http://www.cninfo.com.cn Chinese Name of the Company English Name of the Company Legal Representative Company Secretary Telephone Number Facsimile Number E-mail Address of Company Secretary Registered Address Office Address Postal Code Website of the Company E-mail Address of the Company PRC newspapers for information disclosure Website for annual reports of the Company Listing information (“”)The Stock Exchange of Hong Kong Limited (“SEHK”)Shandong Xinhua00719 HH SharesStock Short NameStock Code Shenzhen Stock ExchangeXinhua Pharm000756 AA SharesStock Short NameStock Code 199393030 September 1993 Date of First Registration Date of Latest Registration 2024103030 October 2024 Place of Registration Zibo Municipal Administration of Market Supervision of ShandongProvince Unified Social Credit Code 91370300164103727C Auditors 225:100004Grant Thornton Zhitong Certified Public Accountants LLP (specialgeneral partnership), 5th Floor, Set Plaza, No. 22 JianguomenwaiStreet, Chaoyang District, Beijing, China Postal Code: 100004 PRC Legal Advisers 43–591201Charltons12/F, Dominion Centre 43–59 Queen’s Road East, Wanchai,Hong Kong 77334100025Jingtian Gongcheng Associates34th Floor, 3 Building, Huamao Center, 77 Jianguo Road,Chaoyang District, Beijing 100025, PRC 2The Industrial and Commercial Bank of China Co., Ltd, ZiboZhangdian Branch2 Renmin Dong Road, Zibo City, Shandong Province, PRC Principal Banker 18317Computershare Hong Kong Investor Services Limited17th Floor, Hopewell Centre,183 Queen’s Road East, Hong Kong Corporate Information Available at Secretariat to the Board of DirectorsShandong Xinhua Pharmaceutical Company Limited . 1.Financial Summary . 1.Financial Summary (Continued) 1. (1)Principal Financial Data (prepared in accordance withChina Accounting Standards for Business Enterprises(“CASBE”) (audited) (Renminbi (“RMB”)) (Continued) Notes: 1.1620232022 1.According to Interpretation of Accounting Standards for BusinessEnterprises No. 16, “Deferred income tax related to assetsand liabilities arising from single transactions does not apply tothe accounting treatment of initial recognition exemption”, theCompany has retroactively adjusted the relevant data of thefinancial statements for 2022 and the previous years in 2023,and the adjustment has not had a significant impact on theCompany’s operations. 2.2 0 2 11 23 12021A2021A736.892 0 2 40.6814 2.From the end of the Reporting Period to the date of this report,7.3689 million new A-shares were issued due to the exercise ofshare options that were exercisable under the second exerciseperiod of the initial grant of the 2021 A-Share Option Scheme ofthe Company adopted on 31 December 2021 (the “2021 A ShareOption Incentive Plan”). The fully diluted earnings per share for2024 using the latest total share capital is RMB0.6814. Note:There are no significant variances between the above financialdata or its amount and the relevant disclosures in the quarterlyreports an